While choosing appropriate management strategy for patients with MCL, one needs to consider the following factors: assessment of physical fitness (performance status, or frailty in the elderly), comorbidities, disease stage, blastoid /non‐blastoid morphology, Ki‐67/MIPI score, access to therapy in various countries, cost‐coverage and availability of ongoing clinical trials.24 This evidence concerns the gene MKI67 and mantle cell lymphoma.